nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—SLC47A1—Mitoxantrone—multiple sclerosis	0.114	0.233	CbGbCtD
Imatinib—ALB—multiple sclerosis	0.114	1	CbGaD
Imatinib—SLC22A2—Cladribine—multiple sclerosis	0.0484	0.099	CbGbCtD
Imatinib—SLC22A1—Cladribine—multiple sclerosis	0.042	0.086	CbGbCtD
Imatinib—ABCG2—Cladribine—multiple sclerosis	0.0357	0.0731	CbGbCtD
Imatinib—ABCG2—Mitoxantrone—multiple sclerosis	0.0261	0.0533	CbGbCtD
Imatinib—CYP2D6—Fingolimod—multiple sclerosis	0.0188	0.0385	CbGbCtD
Imatinib—ALB—Prednisone—multiple sclerosis	0.0149	0.0305	CbGbCtD
Imatinib—ABCG2—Dexamethasone—multiple sclerosis	0.0135	0.0276	CbGbCtD
Imatinib—ABCB1—Methylprednisolone—multiple sclerosis	0.0129	0.0263	CbGbCtD
Imatinib—CYP3A4—Fingolimod—multiple sclerosis	0.012	0.0245	CbGbCtD
Imatinib—ABCG2—Methotrexate—multiple sclerosis	0.0109	0.0222	CbGbCtD
Imatinib—CYP3A7—Dexamethasone—multiple sclerosis	0.00998	0.0204	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Dexamethasone—multiple sclerosis	0.00998	0.0204	CbGbCtD
Imatinib—CYP2C19—Prednisone—multiple sclerosis	0.00967	0.0198	CbGbCtD
Imatinib—ABCB1—Mitoxantrone—multiple sclerosis	0.00939	0.0192	CbGbCtD
Imatinib—ABCB1—Betamethasone—multiple sclerosis	0.00837	0.0171	CbGbCtD
Imatinib—ABCB1—Prednisolone—multiple sclerosis	0.00826	0.0169	CbGbCtD
Imatinib—ABCB1—Prednisone—multiple sclerosis	0.0078	0.016	CbGbCtD
Imatinib—CYP3A4—Methylprednisolone—multiple sclerosis	0.00772	0.0158	CbGbCtD
Imatinib—CYP3A5—Dexamethasone—multiple sclerosis	0.00748	0.0153	CbGbCtD
Imatinib—ALB—Methotrexate—multiple sclerosis	0.00748	0.0153	CbGbCtD
Imatinib—CYP2C19—Dexamethasone—multiple sclerosis	0.00604	0.0123	CbGbCtD
Imatinib—CYP3A4—Triamcinolone—multiple sclerosis	0.00585	0.012	CbGbCtD
Imatinib—CYP3A4—Mitoxantrone—multiple sclerosis	0.00563	0.0115	CbGbCtD
Imatinib—CYP2C9—Dexamethasone—multiple sclerosis	0.00502	0.0103	CbGbCtD
Imatinib—CYP3A4—Betamethasone—multiple sclerosis	0.00502	0.0103	CbGbCtD
Imatinib—CYP3A4—Prednisolone—multiple sclerosis	0.00495	0.0101	CbGbCtD
Imatinib—ABCB1—Dexamethasone—multiple sclerosis	0.00487	0.00996	CbGbCtD
Imatinib—CYP3A4—Prednisone—multiple sclerosis	0.00467	0.00956	CbGbCtD
Imatinib—CYP2D6—Dexamethasone—multiple sclerosis	0.00459	0.00939	CbGbCtD
Imatinib—ABCB1—Methotrexate—multiple sclerosis	0.00391	0.00801	CbGbCtD
Imatinib—CYP3A4—Dexamethasone—multiple sclerosis	0.00292	0.00597	CbGbCtD
Imatinib—NTRK1—midbrain—multiple sclerosis	0.00172	0.0262	CbGeAlD
Imatinib—CA1—nerve—multiple sclerosis	0.00152	0.0231	CbGeAlD
Imatinib—ABCA3—medulla oblongata—multiple sclerosis	0.00149	0.0227	CbGeAlD
Imatinib—DDR1—medulla oblongata—multiple sclerosis	0.00137	0.0209	CbGeAlD
Imatinib—ABCA3—midbrain—multiple sclerosis	0.00136	0.0207	CbGeAlD
Imatinib—ABCA3—spinal cord—multiple sclerosis	0.00133	0.0202	CbGeAlD
Imatinib—DDR1—midbrain—multiple sclerosis	0.00126	0.0191	CbGeAlD
Imatinib—DDR1—spinal cord—multiple sclerosis	0.00122	0.0187	CbGeAlD
Imatinib—PIP4K2C—retina—multiple sclerosis	0.00117	0.0179	CbGeAlD
Imatinib—ABCA3—nervous system—multiple sclerosis	0.00112	0.0171	CbGeAlD
Imatinib—ABCA3—central nervous system—multiple sclerosis	0.00108	0.0164	CbGeAlD
Imatinib—ABCA3—cerebellum—multiple sclerosis	0.00105	0.016	CbGeAlD
Imatinib—DDR1—cerebellum—multiple sclerosis	0.000971	0.0148	CbGeAlD
Imatinib—NQO2—brainstem—multiple sclerosis	0.000893	0.0136	CbGeAlD
Imatinib—HIPK4—brain—multiple sclerosis	0.000864	0.0132	CbGeAlD
Imatinib—ABCA3—brain—multiple sclerosis	0.000855	0.013	CbGeAlD
Imatinib—PIP4K2C—medulla oblongata—multiple sclerosis	0.000848	0.0129	CbGeAlD
Imatinib—CA7—midbrain—multiple sclerosis	0.000807	0.0123	CbGeAlD
Imatinib—DDR1—brain—multiple sclerosis	0.000789	0.012	CbGeAlD
Imatinib—PIP4K2C—midbrain—multiple sclerosis	0.000775	0.0118	CbGeAlD
Imatinib—PIP4K2C—spinal cord—multiple sclerosis	0.000756	0.0115	CbGeAlD
Imatinib—CA14—medulla oblongata—multiple sclerosis	0.000735	0.0112	CbGeAlD
Imatinib—SLC47A1—brainstem—multiple sclerosis	0.000716	0.0109	CbGeAlD
Imatinib—KIT—brainstem—multiple sclerosis	0.000712	0.0109	CbGeAlD
Imatinib—CA14—midbrain—multiple sclerosis	0.000672	0.0102	CbGeAlD
Imatinib—CA14—spinal cord—multiple sclerosis	0.000656	0.00999	CbGeAlD
Imatinib—PIP4K2C—nervous system—multiple sclerosis	0.000637	0.00971	CbGeAlD
Imatinib—ABL2—cerebellum—multiple sclerosis	0.000634	0.00966	CbGeAlD
Imatinib—CA7—cerebellum—multiple sclerosis	0.000624	0.00951	CbGeAlD
Imatinib—NQO2—medulla oblongata—multiple sclerosis	0.000623	0.00949	CbGeAlD
Imatinib—ABL1—brainstem—multiple sclerosis	0.00062	0.00945	CbGeAlD
Imatinib—PIP4K2C—central nervous system—multiple sclerosis	0.000613	0.00935	CbGeAlD
Imatinib—CA3—nervous system—multiple sclerosis	0.000608	0.00927	CbGeAlD
Imatinib—PIP4K2C—cerebellum—multiple sclerosis	0.000599	0.00914	CbGeAlD
Imatinib—ABL1—retina—multiple sclerosis	0.000598	0.00912	CbGeAlD
Imatinib—CA3—central nervous system—multiple sclerosis	0.000586	0.00893	CbGeAlD
Imatinib—NQO2—midbrain—multiple sclerosis	0.000569	0.00868	CbGeAlD
Imatinib—NQO2—spinal cord—multiple sclerosis	0.000555	0.00847	CbGeAlD
Imatinib—PDGFRA—spinal cord—multiple sclerosis	0.000554	0.00844	CbGeAlD
Imatinib—CA9—cerebellum—multiple sclerosis	0.000548	0.00835	CbGeAlD
Imatinib—CSF1R—medulla oblongata—multiple sclerosis	0.000547	0.00834	CbGeAlD
Imatinib—CA14—cerebellum—multiple sclerosis	0.00052	0.00792	CbGeAlD
Imatinib—ABL2—brain—multiple sclerosis	0.000515	0.00785	CbGeAlD
Imatinib—CA7—brain—multiple sclerosis	0.000507	0.00773	CbGeAlD
Imatinib—CSF1R—midbrain—multiple sclerosis	0.0005	0.00762	CbGeAlD
Imatinib—SLC47A1—medulla oblongata—multiple sclerosis	0.000499	0.00761	CbGeAlD
Imatinib—KIT—medulla oblongata—multiple sclerosis	0.000497	0.00757	CbGeAlD
Imatinib—CSF1R—spinal cord—multiple sclerosis	0.000488	0.00743	CbGeAlD
Imatinib—PIP4K2C—brain—multiple sclerosis	0.000487	0.00742	CbGeAlD
Imatinib—PDGFRB—medulla oblongata—multiple sclerosis	0.000485	0.00739	CbGeAlD
Imatinib—NQO2—nervous system—multiple sclerosis	0.000468	0.00713	CbGeAlD
Imatinib—PDGFRA—nervous system—multiple sclerosis	0.000467	0.00712	CbGeAlD
Imatinib—CA3—brain—multiple sclerosis	0.000465	0.00709	CbGeAlD
Imatinib—KIT—midbrain—multiple sclerosis	0.000454	0.00692	CbGeAlD
Imatinib—NQO2—central nervous system—multiple sclerosis	0.00045	0.00687	CbGeAlD
Imatinib—PDGFRA—central nervous system—multiple sclerosis	0.000449	0.00685	CbGeAlD
Imatinib—SLC47A1—spinal cord—multiple sclerosis	0.000445	0.00679	CbGeAlD
Imatinib—PDGFRB—midbrain—multiple sclerosis	0.000443	0.00676	CbGeAlD
Imatinib—KIT—spinal cord—multiple sclerosis	0.000443	0.00675	CbGeAlD
Imatinib—NQO2—cerebellum—multiple sclerosis	0.00044	0.00671	CbGeAlD
Imatinib—PDGFRA—cerebellum—multiple sclerosis	0.000439	0.0067	CbGeAlD
Imatinib—PDGFRB—spinal cord—multiple sclerosis	0.000432	0.00659	CbGeAlD
Imatinib—ABL1—medulla oblongata—multiple sclerosis	0.000432	0.00659	CbGeAlD
Imatinib—CA12—nervous system—multiple sclerosis	0.000431	0.00657	CbGeAlD
Imatinib—CA14—brain—multiple sclerosis	0.000422	0.00644	CbGeAlD
Imatinib—CA2—brainstem—multiple sclerosis	0.000422	0.00644	CbGeAlD
Imatinib—CA12—central nervous system—multiple sclerosis	0.000415	0.00632	CbGeAlD
Imatinib—CSF1R—nervous system—multiple sclerosis	0.000411	0.00626	CbGeAlD
Imatinib—CA2—retina—multiple sclerosis	0.000407	0.00621	CbGeAlD
Imatinib—ORM1—spinal cord—multiple sclerosis	0.000406	0.00618	CbGeAlD
Imatinib—CA1—spinal cord—multiple sclerosis	0.000405	0.00617	CbGeAlD
Imatinib—CSF1R—central nervous system—multiple sclerosis	0.000396	0.00603	CbGeAlD
Imatinib—ABL1—midbrain—multiple sclerosis	0.000395	0.00602	CbGeAlD
Imatinib—CSF1R—cerebellum—multiple sclerosis	0.000387	0.00589	CbGeAlD
Imatinib—ABL1—spinal cord—multiple sclerosis	0.000385	0.00588	CbGeAlD
Imatinib—SLC47A1—nervous system—multiple sclerosis	0.000375	0.00572	CbGeAlD
Imatinib—KIT—nervous system—multiple sclerosis	0.000373	0.00569	CbGeAlD
Imatinib—PDGFRB—nervous system—multiple sclerosis	0.000364	0.00556	CbGeAlD
Imatinib—SLC47A1—central nervous system—multiple sclerosis	0.000361	0.00551	CbGeAlD
Imatinib—KIT—central nervous system—multiple sclerosis	0.000359	0.00548	CbGeAlD
Imatinib—NQO2—brain—multiple sclerosis	0.000358	0.00545	CbGeAlD
Imatinib—PDGFRA—brain—multiple sclerosis	0.000357	0.00544	CbGeAlD
Imatinib—SLC47A1—cerebellum—multiple sclerosis	0.000353	0.00538	CbGeAlD
Imatinib—KIT—cerebellum—multiple sclerosis	0.000351	0.00535	CbGeAlD
Imatinib—PDGFRB—central nervous system—multiple sclerosis	0.000351	0.00535	CbGeAlD
Imatinib—PDGFRB—cerebellum—multiple sclerosis	0.000343	0.00523	CbGeAlD
Imatinib—ORM1—nervous system—multiple sclerosis	0.000342	0.00521	CbGeAlD
Imatinib—CA1—nervous system—multiple sclerosis	0.000341	0.0052	CbGeAlD
Imatinib—CA12—brain—multiple sclerosis	0.000329	0.00502	CbGeAlD
Imatinib—ORM1—central nervous system—multiple sclerosis	0.000329	0.00502	CbGeAlD
Imatinib—CA1—central nervous system—multiple sclerosis	0.000329	0.00501	CbGeAlD
Imatinib—ABL1—nervous system—multiple sclerosis	0.000325	0.00495	CbGeAlD
Imatinib—CSF1R—brain—multiple sclerosis	0.000314	0.00479	CbGeAlD
Imatinib—SLC22A1—nervous system—multiple sclerosis	0.000313	0.00477	CbGeAlD
Imatinib—ABL1—central nervous system—multiple sclerosis	0.000313	0.00477	CbGeAlD
Imatinib—ABL1—cerebellum—multiple sclerosis	0.000306	0.00466	CbGeAlD
Imatinib—SLC22A1—central nervous system—multiple sclerosis	0.000301	0.0046	CbGeAlD
Imatinib—CA2—medulla oblongata—multiple sclerosis	0.000294	0.00449	CbGeAlD
Imatinib—SLC47A1—brain—multiple sclerosis	0.000287	0.00437	CbGeAlD
Imatinib—KIT—brain—multiple sclerosis	0.000285	0.00435	CbGeAlD
Imatinib—PDGFRB—brain—multiple sclerosis	0.000279	0.00425	CbGeAlD
Imatinib—ABCG2—medulla oblongata—multiple sclerosis	0.000273	0.00416	CbGeAlD
Imatinib—CA2—midbrain—multiple sclerosis	0.000269	0.0041	CbGeAlD
Imatinib—CYP2D6—brainstem—multiple sclerosis	0.000268	0.00409	CbGeAlD
Imatinib—CA2—spinal cord—multiple sclerosis	0.000262	0.004	CbGeAlD
Imatinib—CA1—brain—multiple sclerosis	0.000261	0.00398	CbGeAlD
Imatinib—ABCG2—midbrain—multiple sclerosis	0.000249	0.0038	CbGeAlD
Imatinib—ABL1—brain—multiple sclerosis	0.000248	0.00378	CbGeAlD
Imatinib—ABCG2—spinal cord—multiple sclerosis	0.000243	0.00371	CbGeAlD
Imatinib—SLC22A1—brain—multiple sclerosis	0.000239	0.00365	CbGeAlD
Imatinib—ALB—brain—multiple sclerosis	0.000229	0.00349	CbGeAlD
Imatinib—CA2—nervous system—multiple sclerosis	0.000221	0.00337	CbGeAlD
Imatinib—CA2—central nervous system—multiple sclerosis	0.000213	0.00325	CbGeAlD
Imatinib—CA2—cerebellum—multiple sclerosis	0.000208	0.00317	CbGeAlD
Imatinib—PTGS1—spinal cord—multiple sclerosis	0.000203	0.00309	CbGeAlD
Imatinib—ABCG2—cerebellum—multiple sclerosis	0.000193	0.00294	CbGeAlD
Imatinib—ABCB1—retina—multiple sclerosis	0.000186	0.00284	CbGeAlD
Imatinib—PTGS1—nervous system—multiple sclerosis	0.000171	0.0026	CbGeAlD
Imatinib—CA2—brain—multiple sclerosis	0.000169	0.00258	CbGeAlD
Imatinib—PTGS1—central nervous system—multiple sclerosis	0.000164	0.00251	CbGeAlD
Imatinib—ABCG2—brain—multiple sclerosis	0.000157	0.00239	CbGeAlD
Imatinib—CYP3A4—nervous system—multiple sclerosis	0.000143	0.00218	CbGeAlD
Imatinib—CYP2D6—nervous system—multiple sclerosis	0.00014	0.00214	CbGeAlD
Imatinib—CYP3A4—central nervous system—multiple sclerosis	0.000137	0.00209	CbGeAlD
Imatinib—CYP2D6—central nervous system—multiple sclerosis	0.000135	0.00206	CbGeAlD
Imatinib—ABCB1—medulla oblongata—multiple sclerosis	0.000134	0.00205	CbGeAlD
Imatinib—CYP2D6—cerebellum—multiple sclerosis	0.000132	0.00201	CbGeAlD
Imatinib—PTGS1—brain—multiple sclerosis	0.000131	0.00199	CbGeAlD
Imatinib—ABCB1—midbrain—multiple sclerosis	0.000123	0.00187	CbGeAlD
Imatinib—ABCB1—spinal cord—multiple sclerosis	0.00012	0.00183	CbGeAlD
Imatinib—CYP2D6—brain—multiple sclerosis	0.000107	0.00164	CbGeAlD
Imatinib—ABCB1—nervous system—multiple sclerosis	0.000101	0.00154	CbGeAlD
Imatinib—ABCB1—central nervous system—multiple sclerosis	9.72e-05	0.00148	CbGeAlD
Imatinib—ABCB1—cerebellum—multiple sclerosis	9.5e-05	0.00145	CbGeAlD
Imatinib—ABCB1—brain—multiple sclerosis	7.72e-05	0.00118	CbGeAlD
Imatinib—Nausea—Azathioprine—multiple sclerosis	7.2e-05	0.000351	CcSEcCtD
Imatinib—Tachycardia—Methylprednisolone—multiple sclerosis	7.2e-05	0.000351	CcSEcCtD
Imatinib—Skin disorder—Methylprednisolone—multiple sclerosis	7.17e-05	0.000349	CcSEcCtD
Imatinib—Malnutrition—Prednisone—multiple sclerosis	7.16e-05	0.000349	CcSEcCtD
Imatinib—Erythema—Prednisone—multiple sclerosis	7.16e-05	0.000349	CcSEcCtD
Imatinib—Hyperhidrosis—Triamcinolone—multiple sclerosis	7.15e-05	0.000349	CcSEcCtD
Imatinib—Agranulocytosis—Methotrexate—multiple sclerosis	7.15e-05	0.000348	CcSEcCtD
Imatinib—Hyperhidrosis—Methylprednisolone—multiple sclerosis	7.13e-05	0.000348	CcSEcCtD
Imatinib—Convulsion—Betamethasone—multiple sclerosis	7.13e-05	0.000347	CcSEcCtD
Imatinib—Convulsion—Dexamethasone—multiple sclerosis	7.13e-05	0.000347	CcSEcCtD
Imatinib—Hypertension—Dexamethasone—multiple sclerosis	7.1e-05	0.000346	CcSEcCtD
Imatinib—Hypertension—Betamethasone—multiple sclerosis	7.1e-05	0.000346	CcSEcCtD
Imatinib—Asthenia—Mitoxantrone—multiple sclerosis	7.03e-05	0.000343	CcSEcCtD
Imatinib—Myalgia—Betamethasone—multiple sclerosis	7e-05	0.000341	CcSEcCtD
Imatinib—Myalgia—Dexamethasone—multiple sclerosis	7e-05	0.000341	CcSEcCtD
Imatinib—Anxiety—Betamethasone—multiple sclerosis	6.98e-05	0.00034	CcSEcCtD
Imatinib—Anxiety—Dexamethasone—multiple sclerosis	6.98e-05	0.00034	CcSEcCtD
Imatinib—Discomfort—Dexamethasone—multiple sclerosis	6.92e-05	0.000337	CcSEcCtD
Imatinib—Discomfort—Betamethasone—multiple sclerosis	6.92e-05	0.000337	CcSEcCtD
Imatinib—Haemoglobin—Methotrexate—multiple sclerosis	6.91e-05	0.000337	CcSEcCtD
Imatinib—Hypotension—Methylprednisolone—multiple sclerosis	6.9e-05	0.000336	CcSEcCtD
Imatinib—Pain—Prednisolone—multiple sclerosis	6.88e-05	0.000335	CcSEcCtD
Imatinib—Haemorrhage—Methotrexate—multiple sclerosis	6.88e-05	0.000335	CcSEcCtD
Imatinib—Hepatitis—Methotrexate—multiple sclerosis	6.88e-05	0.000335	CcSEcCtD
Imatinib—Pharyngitis—Methotrexate—multiple sclerosis	6.82e-05	0.000333	CcSEcCtD
Imatinib—Urinary tract disorder—Methotrexate—multiple sclerosis	6.79e-05	0.000331	CcSEcCtD
Imatinib—Vision blurred—Prednisone—multiple sclerosis	6.75e-05	0.000329	CcSEcCtD
Imatinib—Urethral disorder—Methotrexate—multiple sclerosis	6.74e-05	0.000329	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	6.74e-05	0.000329	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	6.72e-05	0.000328	CcSEcCtD
Imatinib—Oedema—Betamethasone—multiple sclerosis	6.71e-05	0.000327	CcSEcCtD
Imatinib—Anaphylactic shock—Betamethasone—multiple sclerosis	6.71e-05	0.000327	CcSEcCtD
Imatinib—Oedema—Dexamethasone—multiple sclerosis	6.71e-05	0.000327	CcSEcCtD
Imatinib—Anaphylactic shock—Dexamethasone—multiple sclerosis	6.71e-05	0.000327	CcSEcCtD
Imatinib—Diarrhoea—Mitoxantrone—multiple sclerosis	6.71e-05	0.000327	CcSEcCtD
Imatinib—Insomnia—Triamcinolone—multiple sclerosis	6.69e-05	0.000326	CcSEcCtD
Imatinib—Insomnia—Methylprednisolone—multiple sclerosis	6.68e-05	0.000325	CcSEcCtD
Imatinib—Infection—Betamethasone—multiple sclerosis	6.67e-05	0.000325	CcSEcCtD
Imatinib—Infection—Dexamethasone—multiple sclerosis	6.67e-05	0.000325	CcSEcCtD
Imatinib—Ill-defined disorder—Prednisone—multiple sclerosis	6.64e-05	0.000324	CcSEcCtD
Imatinib—Paraesthesia—Triamcinolone—multiple sclerosis	6.64e-05	0.000324	CcSEcCtD
Imatinib—Feeling abnormal—Prednisolone—multiple sclerosis	6.63e-05	0.000323	CcSEcCtD
Imatinib—Paraesthesia—Methylprednisolone—multiple sclerosis	6.63e-05	0.000323	CcSEcCtD
Imatinib—Anaemia—Prednisone—multiple sclerosis	6.62e-05	0.000323	CcSEcCtD
Imatinib—Shock—Dexamethasone—multiple sclerosis	6.6e-05	0.000322	CcSEcCtD
Imatinib—Shock—Betamethasone—multiple sclerosis	6.6e-05	0.000322	CcSEcCtD
Imatinib—Dyspnoea—Triamcinolone—multiple sclerosis	6.59e-05	0.000321	CcSEcCtD
Imatinib—Nervous system disorder—Betamethasone—multiple sclerosis	6.58e-05	0.000321	CcSEcCtD
Imatinib—Nervous system disorder—Dexamethasone—multiple sclerosis	6.58e-05	0.000321	CcSEcCtD
Imatinib—Thrombocytopenia—Dexamethasone—multiple sclerosis	6.57e-05	0.00032	CcSEcCtD
Imatinib—Thrombocytopenia—Betamethasone—multiple sclerosis	6.57e-05	0.00032	CcSEcCtD
Imatinib—Tachycardia—Dexamethasone—multiple sclerosis	6.55e-05	0.000319	CcSEcCtD
Imatinib—Tachycardia—Betamethasone—multiple sclerosis	6.55e-05	0.000319	CcSEcCtD
Imatinib—Angioedema—Prednisone—multiple sclerosis	6.54e-05	0.000319	CcSEcCtD
Imatinib—Dyspepsia—Triamcinolone—multiple sclerosis	6.51e-05	0.000317	CcSEcCtD
Imatinib—Erythema multiforme—Methotrexate—multiple sclerosis	6.5e-05	0.000317	CcSEcCtD
Imatinib—Dyspepsia—Methylprednisolone—multiple sclerosis	6.5e-05	0.000317	CcSEcCtD
Imatinib—Hyperhidrosis—Betamethasone—multiple sclerosis	6.49e-05	0.000316	CcSEcCtD
Imatinib—Hyperhidrosis—Dexamethasone—multiple sclerosis	6.49e-05	0.000316	CcSEcCtD
Imatinib—Malaise—Prednisone—multiple sclerosis	6.46e-05	0.000315	CcSEcCtD
Imatinib—Vertigo—Prednisone—multiple sclerosis	6.43e-05	0.000314	CcSEcCtD
Imatinib—Eye disorder—Methotrexate—multiple sclerosis	6.43e-05	0.000313	CcSEcCtD
Imatinib—Syncope—Prednisone—multiple sclerosis	6.42e-05	0.000313	CcSEcCtD
Imatinib—Tinnitus—Methotrexate—multiple sclerosis	6.41e-05	0.000312	CcSEcCtD
Imatinib—Anorexia—Dexamethasone—multiple sclerosis	6.4e-05	0.000312	CcSEcCtD
Imatinib—Anorexia—Betamethasone—multiple sclerosis	6.4e-05	0.000312	CcSEcCtD
Imatinib—Urticaria—Prednisolone—multiple sclerosis	6.39e-05	0.000311	CcSEcCtD
Imatinib—Cardiac disorder—Methotrexate—multiple sclerosis	6.38e-05	0.000311	CcSEcCtD
Imatinib—Fatigue—Triamcinolone—multiple sclerosis	6.38e-05	0.000311	CcSEcCtD
Imatinib—Fatigue—Methylprednisolone—multiple sclerosis	6.36e-05	0.00031	CcSEcCtD
Imatinib—Pain—Triamcinolone—multiple sclerosis	6.33e-05	0.000308	CcSEcCtD
Imatinib—Loss of consciousness—Prednisone—multiple sclerosis	6.29e-05	0.000307	CcSEcCtD
Imatinib—Hypotension—Dexamethasone—multiple sclerosis	6.27e-05	0.000306	CcSEcCtD
Imatinib—Hypotension—Betamethasone—multiple sclerosis	6.27e-05	0.000306	CcSEcCtD
Imatinib—Angiopathy—Methotrexate—multiple sclerosis	6.24e-05	0.000304	CcSEcCtD
Imatinib—Vomiting—Mitoxantrone—multiple sclerosis	6.23e-05	0.000304	CcSEcCtD
Imatinib—Immune system disorder—Methotrexate—multiple sclerosis	6.21e-05	0.000303	CcSEcCtD
Imatinib—Convulsion—Prednisone—multiple sclerosis	6.21e-05	0.000302	CcSEcCtD
Imatinib—Mediastinal disorder—Methotrexate—multiple sclerosis	6.2e-05	0.000302	CcSEcCtD
Imatinib—Hypertension—Prednisone—multiple sclerosis	6.18e-05	0.000301	CcSEcCtD
Imatinib—Rash—Mitoxantrone—multiple sclerosis	6.18e-05	0.000301	CcSEcCtD
Imatinib—Dermatitis—Mitoxantrone—multiple sclerosis	6.18e-05	0.000301	CcSEcCtD
Imatinib—Chills—Methotrexate—multiple sclerosis	6.17e-05	0.000301	CcSEcCtD
Imatinib—Headache—Mitoxantrone—multiple sclerosis	6.14e-05	0.000299	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	6.11e-05	0.000298	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	6.11e-05	0.000298	CcSEcCtD
Imatinib—Arthralgia—Prednisone—multiple sclerosis	6.1e-05	0.000297	CcSEcCtD
Imatinib—Myalgia—Prednisone—multiple sclerosis	6.1e-05	0.000297	CcSEcCtD
Imatinib—Feeling abnormal—Triamcinolone—multiple sclerosis	6.1e-05	0.000297	CcSEcCtD
Imatinib—Feeling abnormal—Methylprednisolone—multiple sclerosis	6.08e-05	0.000296	CcSEcCtD
Imatinib—Anxiety—Prednisone—multiple sclerosis	6.08e-05	0.000296	CcSEcCtD
Imatinib—Alopecia—Methotrexate—multiple sclerosis	6.08e-05	0.000296	CcSEcCtD
Imatinib—Insomnia—Dexamethasone—multiple sclerosis	6.07e-05	0.000296	CcSEcCtD
Imatinib—Insomnia—Betamethasone—multiple sclerosis	6.07e-05	0.000296	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	6.06e-05	0.000295	CcSEcCtD
Imatinib—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	6.04e-05	0.000294	CcSEcCtD
Imatinib—Paraesthesia—Dexamethasone—multiple sclerosis	6.03e-05	0.000294	CcSEcCtD
Imatinib—Paraesthesia—Betamethasone—multiple sclerosis	6.03e-05	0.000294	CcSEcCtD
Imatinib—Discomfort—Prednisone—multiple sclerosis	6.02e-05	0.000294	CcSEcCtD
Imatinib—Mental disorder—Methotrexate—multiple sclerosis	6.02e-05	0.000294	CcSEcCtD
Imatinib—Malnutrition—Methotrexate—multiple sclerosis	5.99e-05	0.000292	CcSEcCtD
Imatinib—Erythema—Methotrexate—multiple sclerosis	5.99e-05	0.000292	CcSEcCtD
Imatinib—Hypersensitivity—Prednisolone—multiple sclerosis	5.93e-05	0.000289	CcSEcCtD
Imatinib—Dyspepsia—Dexamethasone—multiple sclerosis	5.91e-05	0.000288	CcSEcCtD
Imatinib—Dyspepsia—Betamethasone—multiple sclerosis	5.91e-05	0.000288	CcSEcCtD
Imatinib—Urticaria—Triamcinolone—multiple sclerosis	5.88e-05	0.000286	CcSEcCtD
Imatinib—Urticaria—Methylprednisolone—multiple sclerosis	5.86e-05	0.000286	CcSEcCtD
Imatinib—Dysgeusia—Methotrexate—multiple sclerosis	5.86e-05	0.000286	CcSEcCtD
Imatinib—Body temperature increased—Triamcinolone—multiple sclerosis	5.85e-05	0.000285	CcSEcCtD
Imatinib—Oedema—Prednisone—multiple sclerosis	5.84e-05	0.000285	CcSEcCtD
Imatinib—Anaphylactic shock—Prednisone—multiple sclerosis	5.84e-05	0.000285	CcSEcCtD
Imatinib—Abdominal pain—Methylprednisolone—multiple sclerosis	5.83e-05	0.000284	CcSEcCtD
Imatinib—Decreased appetite—Dexamethasone—multiple sclerosis	5.83e-05	0.000284	CcSEcCtD
Imatinib—Decreased appetite—Betamethasone—multiple sclerosis	5.83e-05	0.000284	CcSEcCtD
Imatinib—Nausea—Mitoxantrone—multiple sclerosis	5.82e-05	0.000284	CcSEcCtD
Imatinib—Infection—Prednisone—multiple sclerosis	5.81e-05	0.000283	CcSEcCtD
Imatinib—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	5.79e-05	0.000282	CcSEcCtD
Imatinib—Gastrointestinal disorder—Betamethasone—multiple sclerosis	5.79e-05	0.000282	CcSEcCtD
Imatinib—Back pain—Methotrexate—multiple sclerosis	5.79e-05	0.000282	CcSEcCtD
Imatinib—Fatigue—Betamethasone—multiple sclerosis	5.79e-05	0.000282	CcSEcCtD
Imatinib—Fatigue—Dexamethasone—multiple sclerosis	5.79e-05	0.000282	CcSEcCtD
Imatinib—Shock—Prednisone—multiple sclerosis	5.75e-05	0.00028	CcSEcCtD
Imatinib—Pain—Betamethasone—multiple sclerosis	5.74e-05	0.00028	CcSEcCtD
Imatinib—Pain—Dexamethasone—multiple sclerosis	5.74e-05	0.00028	CcSEcCtD
Imatinib—Nervous system disorder—Prednisone—multiple sclerosis	5.73e-05	0.000279	CcSEcCtD
Imatinib—Tachycardia—Prednisone—multiple sclerosis	5.7e-05	0.000278	CcSEcCtD
Imatinib—Skin disorder—Prednisone—multiple sclerosis	5.68e-05	0.000277	CcSEcCtD
Imatinib—Hyperhidrosis—Prednisone—multiple sclerosis	5.65e-05	0.000275	CcSEcCtD
Imatinib—Vision blurred—Methotrexate—multiple sclerosis	5.64e-05	0.000275	CcSEcCtD
Imatinib—Anorexia—Prednisone—multiple sclerosis	5.57e-05	0.000272	CcSEcCtD
Imatinib—Ill-defined disorder—Methotrexate—multiple sclerosis	5.55e-05	0.000271	CcSEcCtD
Imatinib—Anaemia—Methotrexate—multiple sclerosis	5.53e-05	0.00027	CcSEcCtD
Imatinib—Feeling abnormal—Dexamethasone—multiple sclerosis	5.53e-05	0.00027	CcSEcCtD
Imatinib—Feeling abnormal—Betamethasone—multiple sclerosis	5.53e-05	0.00027	CcSEcCtD
Imatinib—Gastrointestinal pain—Betamethasone—multiple sclerosis	5.49e-05	0.000268	CcSEcCtD
Imatinib—Gastrointestinal pain—Dexamethasone—multiple sclerosis	5.49e-05	0.000268	CcSEcCtD
Imatinib—Hypersensitivity—Triamcinolone—multiple sclerosis	5.45e-05	0.000266	CcSEcCtD
Imatinib—Hypersensitivity—Methylprednisolone—multiple sclerosis	5.44e-05	0.000265	CcSEcCtD
Imatinib—Malaise—Methotrexate—multiple sclerosis	5.4e-05	0.000263	CcSEcCtD
Imatinib—Vertigo—Methotrexate—multiple sclerosis	5.38e-05	0.000262	CcSEcCtD
Imatinib—Leukopenia—Methotrexate—multiple sclerosis	5.36e-05	0.000261	CcSEcCtD
Imatinib—Urticaria—Betamethasone—multiple sclerosis	5.33e-05	0.00026	CcSEcCtD
Imatinib—Urticaria—Dexamethasone—multiple sclerosis	5.33e-05	0.00026	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Prednisone—multiple sclerosis	5.33e-05	0.00026	CcSEcCtD
Imatinib—Dizziness—Prednisolone—multiple sclerosis	5.32e-05	0.000259	CcSEcCtD
Imatinib—Asthenia—Triamcinolone—multiple sclerosis	5.31e-05	0.000259	CcSEcCtD
Imatinib—Body temperature increased—Betamethasone—multiple sclerosis	5.31e-05	0.000259	CcSEcCtD
Imatinib—Abdominal pain—Dexamethasone—multiple sclerosis	5.31e-05	0.000259	CcSEcCtD
Imatinib—Body temperature increased—Dexamethasone—multiple sclerosis	5.31e-05	0.000259	CcSEcCtD
Imatinib—Abdominal pain—Betamethasone—multiple sclerosis	5.31e-05	0.000259	CcSEcCtD
Imatinib—Asthenia—Methylprednisolone—multiple sclerosis	5.3e-05	0.000258	CcSEcCtD
Imatinib—Insomnia—Prednisone—multiple sclerosis	5.29e-05	0.000258	CcSEcCtD
Imatinib—Paraesthesia—Prednisone—multiple sclerosis	5.25e-05	0.000256	CcSEcCtD
Imatinib—Pruritus—Triamcinolone—multiple sclerosis	5.23e-05	0.000255	CcSEcCtD
Imatinib—Cough—Methotrexate—multiple sclerosis	5.22e-05	0.000255	CcSEcCtD
Imatinib—Pruritus—Methylprednisolone—multiple sclerosis	5.22e-05	0.000255	CcSEcCtD
Imatinib—Convulsion—Methotrexate—multiple sclerosis	5.19e-05	0.000253	CcSEcCtD
Imatinib—Dyspepsia—Prednisone—multiple sclerosis	5.15e-05	0.000251	CcSEcCtD
Imatinib—Chest pain—Methotrexate—multiple sclerosis	5.1e-05	0.000248	CcSEcCtD
Imatinib—Arthralgia—Methotrexate—multiple sclerosis	5.1e-05	0.000248	CcSEcCtD
Imatinib—Myalgia—Methotrexate—multiple sclerosis	5.1e-05	0.000248	CcSEcCtD
Imatinib—Decreased appetite—Prednisone—multiple sclerosis	5.08e-05	0.000248	CcSEcCtD
Imatinib—Rash—Prednisolone—multiple sclerosis	5.07e-05	0.000247	CcSEcCtD
Imatinib—Dermatitis—Prednisolone—multiple sclerosis	5.07e-05	0.000247	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	5.06e-05	0.000247	CcSEcCtD
Imatinib—Diarrhoea—Methylprednisolone—multiple sclerosis	5.05e-05	0.000246	CcSEcCtD
Imatinib—Fatigue—Prednisone—multiple sclerosis	5.04e-05	0.000246	CcSEcCtD
Imatinib—Headache—Prednisolone—multiple sclerosis	5.04e-05	0.000246	CcSEcCtD
Imatinib—Discomfort—Methotrexate—multiple sclerosis	5.03e-05	0.000245	CcSEcCtD
Imatinib—Constipation—Prednisone—multiple sclerosis	5e-05	0.000244	CcSEcCtD
Imatinib—Confusional state—Methotrexate—multiple sclerosis	4.93e-05	0.00024	CcSEcCtD
Imatinib—Dizziness—Triamcinolone—multiple sclerosis	4.89e-05	0.000238	CcSEcCtD
Imatinib—Anaphylactic shock—Methotrexate—multiple sclerosis	4.88e-05	0.000238	CcSEcCtD
Imatinib—Dizziness—Methylprednisolone—multiple sclerosis	4.88e-05	0.000238	CcSEcCtD
Imatinib—Infection—Methotrexate—multiple sclerosis	4.85e-05	0.000237	CcSEcCtD
Imatinib—Feeling abnormal—Prednisone—multiple sclerosis	4.82e-05	0.000235	CcSEcCtD
Imatinib—Asthenia—Betamethasone—multiple sclerosis	4.82e-05	0.000235	CcSEcCtD
Imatinib—Asthenia—Dexamethasone—multiple sclerosis	4.82e-05	0.000235	CcSEcCtD
Imatinib—Nervous system disorder—Methotrexate—multiple sclerosis	4.79e-05	0.000234	CcSEcCtD
Imatinib—Thrombocytopenia—Methotrexate—multiple sclerosis	4.78e-05	0.000233	CcSEcCtD
Imatinib—Gastrointestinal pain—Prednisone—multiple sclerosis	4.78e-05	0.000233	CcSEcCtD
Imatinib—Nausea—Prednisolone—multiple sclerosis	4.78e-05	0.000233	CcSEcCtD
Imatinib—Pruritus—Dexamethasone—multiple sclerosis	4.75e-05	0.000231	CcSEcCtD
Imatinib—Pruritus—Betamethasone—multiple sclerosis	4.75e-05	0.000231	CcSEcCtD
Imatinib—Skin disorder—Methotrexate—multiple sclerosis	4.74e-05	0.000231	CcSEcCtD
Imatinib—Hyperhidrosis—Methotrexate—multiple sclerosis	4.72e-05	0.00023	CcSEcCtD
Imatinib—Vomiting—Triamcinolone—multiple sclerosis	4.7e-05	0.000229	CcSEcCtD
Imatinib—Vomiting—Methylprednisolone—multiple sclerosis	4.69e-05	0.000229	CcSEcCtD
Imatinib—Rash—Triamcinolone—multiple sclerosis	4.66e-05	0.000227	CcSEcCtD
Imatinib—Dermatitis—Triamcinolone—multiple sclerosis	4.66e-05	0.000227	CcSEcCtD
Imatinib—Anorexia—Methotrexate—multiple sclerosis	4.66e-05	0.000227	CcSEcCtD
Imatinib—Rash—Methylprednisolone—multiple sclerosis	4.65e-05	0.000227	CcSEcCtD
Imatinib—Dermatitis—Methylprednisolone—multiple sclerosis	4.65e-05	0.000227	CcSEcCtD
Imatinib—Urticaria—Prednisone—multiple sclerosis	4.64e-05	0.000226	CcSEcCtD
Imatinib—Headache—Triamcinolone—multiple sclerosis	4.63e-05	0.000226	CcSEcCtD
Imatinib—Headache—Methylprednisolone—multiple sclerosis	4.62e-05	0.000225	CcSEcCtD
Imatinib—Body temperature increased—Prednisone—multiple sclerosis	4.62e-05	0.000225	CcSEcCtD
Imatinib—Abdominal pain—Prednisone—multiple sclerosis	4.62e-05	0.000225	CcSEcCtD
Imatinib—Diarrhoea—Betamethasone—multiple sclerosis	4.59e-05	0.000224	CcSEcCtD
Imatinib—Diarrhoea—Dexamethasone—multiple sclerosis	4.59e-05	0.000224	CcSEcCtD
Imatinib—Hypotension—Methotrexate—multiple sclerosis	4.56e-05	0.000223	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	4.45e-05	0.000217	CcSEcCtD
Imatinib—Dizziness—Betamethasone—multiple sclerosis	4.44e-05	0.000216	CcSEcCtD
Imatinib—Dizziness—Dexamethasone—multiple sclerosis	4.44e-05	0.000216	CcSEcCtD
Imatinib—Insomnia—Methotrexate—multiple sclerosis	4.42e-05	0.000215	CcSEcCtD
Imatinib—Nausea—Triamcinolone—multiple sclerosis	4.39e-05	0.000214	CcSEcCtD
Imatinib—Paraesthesia—Methotrexate—multiple sclerosis	4.39e-05	0.000214	CcSEcCtD
Imatinib—Nausea—Methylprednisolone—multiple sclerosis	4.38e-05	0.000214	CcSEcCtD
Imatinib—Dyspnoea—Methotrexate—multiple sclerosis	4.35e-05	0.000212	CcSEcCtD
Imatinib—Somnolence—Methotrexate—multiple sclerosis	4.34e-05	0.000212	CcSEcCtD
Imatinib—Hypersensitivity—Prednisone—multiple sclerosis	4.31e-05	0.00021	CcSEcCtD
Imatinib—Dyspepsia—Methotrexate—multiple sclerosis	4.3e-05	0.00021	CcSEcCtD
Imatinib—Vomiting—Dexamethasone—multiple sclerosis	4.27e-05	0.000208	CcSEcCtD
Imatinib—Vomiting—Betamethasone—multiple sclerosis	4.27e-05	0.000208	CcSEcCtD
Imatinib—Decreased appetite—Methotrexate—multiple sclerosis	4.25e-05	0.000207	CcSEcCtD
Imatinib—Rash—Betamethasone—multiple sclerosis	4.23e-05	0.000206	CcSEcCtD
Imatinib—Rash—Dexamethasone—multiple sclerosis	4.23e-05	0.000206	CcSEcCtD
Imatinib—Dermatitis—Dexamethasone—multiple sclerosis	4.23e-05	0.000206	CcSEcCtD
Imatinib—Dermatitis—Betamethasone—multiple sclerosis	4.23e-05	0.000206	CcSEcCtD
Imatinib—Gastrointestinal disorder—Methotrexate—multiple sclerosis	4.22e-05	0.000206	CcSEcCtD
Imatinib—Fatigue—Methotrexate—multiple sclerosis	4.21e-05	0.000205	CcSEcCtD
Imatinib—Headache—Dexamethasone—multiple sclerosis	4.2e-05	0.000205	CcSEcCtD
Imatinib—Headache—Betamethasone—multiple sclerosis	4.2e-05	0.000205	CcSEcCtD
Imatinib—Asthenia—Prednisone—multiple sclerosis	4.19e-05	0.000204	CcSEcCtD
Imatinib—Pain—Methotrexate—multiple sclerosis	4.18e-05	0.000204	CcSEcCtD
Imatinib—Pruritus—Prednisone—multiple sclerosis	4.14e-05	0.000202	CcSEcCtD
Imatinib—Feeling abnormal—Methotrexate—multiple sclerosis	4.03e-05	0.000196	CcSEcCtD
Imatinib—Diarrhoea—Prednisone—multiple sclerosis	4e-05	0.000195	CcSEcCtD
Imatinib—Gastrointestinal pain—Methotrexate—multiple sclerosis	3.99e-05	0.000195	CcSEcCtD
Imatinib—Nausea—Dexamethasone—multiple sclerosis	3.99e-05	0.000194	CcSEcCtD
Imatinib—Nausea—Betamethasone—multiple sclerosis	3.99e-05	0.000194	CcSEcCtD
Imatinib—Urticaria—Methotrexate—multiple sclerosis	3.88e-05	0.000189	CcSEcCtD
Imatinib—Dizziness—Prednisone—multiple sclerosis	3.87e-05	0.000188	CcSEcCtD
Imatinib—Abdominal pain—Methotrexate—multiple sclerosis	3.86e-05	0.000188	CcSEcCtD
Imatinib—Body temperature increased—Methotrexate—multiple sclerosis	3.86e-05	0.000188	CcSEcCtD
Imatinib—Vomiting—Prednisone—multiple sclerosis	3.72e-05	0.000181	CcSEcCtD
Imatinib—Rash—Prednisone—multiple sclerosis	3.69e-05	0.00018	CcSEcCtD
Imatinib—Dermatitis—Prednisone—multiple sclerosis	3.68e-05	0.000179	CcSEcCtD
Imatinib—Headache—Prednisone—multiple sclerosis	3.66e-05	0.000178	CcSEcCtD
Imatinib—Hypersensitivity—Methotrexate—multiple sclerosis	3.6e-05	0.000175	CcSEcCtD
Imatinib—Asthenia—Methotrexate—multiple sclerosis	3.5e-05	0.000171	CcSEcCtD
Imatinib—Nausea—Prednisone—multiple sclerosis	3.47e-05	0.000169	CcSEcCtD
Imatinib—Pruritus—Methotrexate—multiple sclerosis	3.46e-05	0.000168	CcSEcCtD
Imatinib—Diarrhoea—Methotrexate—multiple sclerosis	3.34e-05	0.000163	CcSEcCtD
Imatinib—Dizziness—Methotrexate—multiple sclerosis	3.23e-05	0.000157	CcSEcCtD
Imatinib—Vomiting—Methotrexate—multiple sclerosis	3.11e-05	0.000151	CcSEcCtD
Imatinib—Rash—Methotrexate—multiple sclerosis	3.08e-05	0.00015	CcSEcCtD
Imatinib—Dermatitis—Methotrexate—multiple sclerosis	3.08e-05	0.00015	CcSEcCtD
Imatinib—Headache—Methotrexate—multiple sclerosis	3.06e-05	0.000149	CcSEcCtD
Imatinib—Nausea—Methotrexate—multiple sclerosis	2.9e-05	0.000141	CcSEcCtD
Imatinib—CYP1A2—Metabolism—GPC5—multiple sclerosis	8.17e-06	6.46e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CD80—multiple sclerosis	8.15e-06	6.44e-05	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—MAPK1—multiple sclerosis	8.14e-06	6.43e-05	CbGpPWpGaD
Imatinib—LCK—Signaling by NGF—IL6—multiple sclerosis	8.13e-06	6.43e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CD28—multiple sclerosis	8.13e-06	6.42e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—TYK2—multiple sclerosis	8.07e-06	6.38e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CD86—multiple sclerosis	8.02e-06	6.34e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—POMC—multiple sclerosis	8.02e-06	6.33e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—RRM1—multiple sclerosis	7.99e-06	6.32e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CCR2—multiple sclerosis	7.98e-06	6.31e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—CD80—multiple sclerosis	7.95e-06	6.28e-05	CbGpPWpGaD
Imatinib—ALB—Platelet activation, signaling and aggregation—TGFB1—multiple sclerosis	7.93e-06	6.26e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—RRM1—multiple sclerosis	7.92e-06	6.26e-05	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—TNF—multiple sclerosis	7.9e-06	6.24e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CCL5—multiple sclerosis	7.9e-06	6.24e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—CCL2—multiple sclerosis	7.84e-06	6.2e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—IL2RA—multiple sclerosis	7.84e-06	6.19e-05	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	7.83e-06	6.18e-05	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	7.81e-06	6.17e-05	CbGpPWpGaD
Imatinib—ALB—Platelet activation, signaling and aggregation—MAPK1—multiple sclerosis	7.78e-06	6.14e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—HLA-A—multiple sclerosis	7.75e-06	6.12e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—SPP1—multiple sclerosis	7.73e-06	6.1e-05	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	7.66e-06	6.05e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—TYK2—multiple sclerosis	7.64e-06	6.04e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—IFNG—multiple sclerosis	7.56e-06	5.97e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—CD80—multiple sclerosis	7.53e-06	5.95e-05	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—MAPK1—multiple sclerosis	7.52e-06	5.94e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CCR5—multiple sclerosis	7.52e-06	5.94e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	7.51e-06	5.93e-05	CbGpPWpGaD
Imatinib—KIT—Disease—TYK2—multiple sclerosis	7.45e-06	5.89e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—IL2RA—multiple sclerosis	7.41e-06	5.85e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CNR1—multiple sclerosis	7.37e-06	5.82e-05	CbGpPWpGaD
Imatinib—LCK—Disease—CCR5—multiple sclerosis	7.34e-06	5.8e-05	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—MAPK1—multiple sclerosis	7.33e-06	5.79e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—SPP1—multiple sclerosis	7.31e-06	5.78e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—CD4—multiple sclerosis	7.3e-06	5.77e-05	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	7.29e-06	5.76e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CD86—multiple sclerosis	7.23e-06	5.71e-05	CbGpPWpGaD
Imatinib—LCK—Disease—HLA-A—multiple sclerosis	7.16e-06	5.65e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IFNG—multiple sclerosis	7.15e-06	5.65e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—TYK2—multiple sclerosis	7.12e-06	5.63e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CCL5—multiple sclerosis	7.11e-06	5.62e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CCR5—multiple sclerosis	7.11e-06	5.62e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—TLR4—multiple sclerosis	7.09e-06	5.6e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—HLA-DRB1—multiple sclerosis	7.08e-06	5.6e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—TYK2—multiple sclerosis	7.05e-06	5.57e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—IL2RA—multiple sclerosis	7.01e-06	5.54e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—CD4—multiple sclerosis	6.91e-06	5.46e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	6.9e-06	5.45e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	6.9e-06	5.45e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—TYK2—multiple sclerosis	6.88e-06	5.44e-05	CbGpPWpGaD
Imatinib—LCK—Hemostasis—TGFB1—multiple sclerosis	6.84e-06	5.4e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—APOE—multiple sclerosis	6.84e-06	5.4e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—ICAM1—multiple sclerosis	6.8e-06	5.37e-05	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—IL6—multiple sclerosis	6.78e-06	5.35e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—RRM1—multiple sclerosis	6.77e-06	5.35e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	6.74e-06	5.33e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—IL1B—multiple sclerosis	6.74e-06	5.33e-05	CbGpPWpGaD
Imatinib—KIT—Disease—CD4—multiple sclerosis	6.74e-06	5.32e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—IL2—multiple sclerosis	6.72e-06	5.31e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—TYK2—multiple sclerosis	6.71e-06	5.3e-05	CbGpPWpGaD
Imatinib—LCK—Hemostasis—MAPK1—multiple sclerosis	6.71e-06	5.3e-05	CbGpPWpGaD
Imatinib—LCK—Disease—APOE—multiple sclerosis	6.68e-06	5.28e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CXCL10—multiple sclerosis	6.63e-06	5.24e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—SPP1—multiple sclerosis	6.59e-06	5.21e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—CD80—multiple sclerosis	6.54e-06	5.17e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—APOE—multiple sclerosis	6.47e-06	5.11e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—BCHE—multiple sclerosis	6.46e-06	5.1e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	6.45e-06	5.1e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IFNG—multiple sclerosis	6.45e-06	5.09e-05	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—IL6—multiple sclerosis	6.42e-06	5.07e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CCR5—multiple sclerosis	6.41e-06	5.06e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IL1B—multiple sclerosis	6.38e-06	5.04e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—CD4—multiple sclerosis	6.38e-06	5.04e-05	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—IL6—multiple sclerosis	6.38e-06	5.04e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IL2—multiple sclerosis	6.36e-06	5.02e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—TYK2—multiple sclerosis	6.35e-06	5.02e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IL2RA—multiple sclerosis	6.32e-06	4.99e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GPC5—multiple sclerosis	6.31e-06	4.98e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—IFNG—multiple sclerosis	6.28e-06	4.96e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CD4—multiple sclerosis	6.22e-06	4.92e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CD80—multiple sclerosis	6.18e-06	4.88e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	6.15e-06	4.86e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—CD4—multiple sclerosis	6.07e-06	4.79e-05	CbGpPWpGaD
Imatinib—LCK—Disease—CD80—multiple sclerosis	6.04e-06	4.77e-05	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—MAPK1—multiple sclerosis	6.04e-06	4.77e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—IL2—multiple sclerosis	5.93e-06	4.68e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—POMC—multiple sclerosis	5.87e-06	4.64e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CD80—multiple sclerosis	5.85e-06	4.62e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—APOE—multiple sclerosis	5.83e-06	4.61e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CD86—multiple sclerosis	5.8e-06	4.58e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	5.79e-06	4.58e-05	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—IL6—multiple sclerosis	5.78e-06	4.57e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IL1B—multiple sclerosis	5.75e-06	4.54e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—CD4—multiple sclerosis	5.75e-06	4.54e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CCL2—multiple sclerosis	5.75e-06	4.54e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IL2—multiple sclerosis	5.73e-06	4.52e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CCL5—multiple sclerosis	5.71e-06	4.51e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—STAT3—multiple sclerosis	5.65e-06	4.46e-05	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—IL6—multiple sclerosis	5.63e-06	4.45e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—MMP9—multiple sclerosis	5.61e-06	4.43e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—IL1B—multiple sclerosis	5.6e-06	4.43e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—IL2—multiple sclerosis	5.58e-06	4.41e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—BCHE—multiple sclerosis	5.56e-06	4.39e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—POMC—multiple sclerosis	5.56e-06	4.39e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—TYK2—multiple sclerosis	5.52e-06	4.36e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CCL2—multiple sclerosis	5.44e-06	4.3e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—APOE—multiple sclerosis	5.42e-06	4.28e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—APOE—multiple sclerosis	5.37e-06	4.25e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—APOE—multiple sclerosis	5.36e-06	4.24e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—STAT3—multiple sclerosis	5.35e-06	4.23e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—SPP1—multiple sclerosis	5.29e-06	4.18e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	5.28e-06	4.17e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	5.28e-06	4.17e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CD80—multiple sclerosis	5.27e-06	4.16e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	5.25e-06	4.15e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—IL2—multiple sclerosis	5.24e-06	4.14e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—RRM1—multiple sclerosis	5.23e-06	4.13e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TYK2—multiple sclerosis	5.22e-06	4.12e-05	CbGpPWpGaD
Imatinib—KIT—Disease—STAT3—multiple sclerosis	5.22e-06	4.12e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—APOE—multiple sclerosis	5.21e-06	4.11e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—IFNG—multiple sclerosis	5.17e-06	4.09e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CCR5—multiple sclerosis	5.14e-06	4.06e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—MAPK1—multiple sclerosis	5.14e-06	4.06e-05	CbGpPWpGaD
Imatinib—LCK—Disease—TYK2—multiple sclerosis	5.1e-06	4.03e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IL2RA—multiple sclerosis	5.07e-06	4e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—POMC—multiple sclerosis	5.01e-06	3.96e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—APOE—multiple sclerosis	5e-06	3.95e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—CD4—multiple sclerosis	5e-06	3.95e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—BCHE—multiple sclerosis	4.99e-06	3.94e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—STAT3—multiple sclerosis	4.99e-06	3.94e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TYK2—multiple sclerosis	4.94e-06	3.9e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—STAT3—multiple sclerosis	4.94e-06	3.9e-05	CbGpPWpGaD
Imatinib—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	4.9e-06	3.87e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CCL2—multiple sclerosis	4.9e-06	3.87e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—BCHE—multiple sclerosis	4.87e-06	3.85e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—MAPK1—multiple sclerosis	4.86e-06	3.84e-05	CbGpPWpGaD
Imatinib—KIT—Disease—MYC—multiple sclerosis	4.85e-06	3.83e-05	CbGpPWpGaD
Imatinib—KIT—Disease—TGFB1—multiple sclerosis	4.84e-06	3.82e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—STAT3—multiple sclerosis	4.82e-06	3.81e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	4.82e-06	3.8e-05	CbGpPWpGaD
Imatinib—KIT—Disease—MAPK1—multiple sclerosis	4.74e-06	3.75e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—STAT3—multiple sclerosis	4.7e-06	3.71e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—APOE—multiple sclerosis	4.68e-06	3.7e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—POMC—multiple sclerosis	4.66e-06	3.68e-05	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—IL6—multiple sclerosis	4.64e-06	3.66e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—MYC—multiple sclerosis	4.63e-06	3.66e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—TGFB1—multiple sclerosis	4.62e-06	3.65e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—POMC—multiple sclerosis	4.62e-06	3.65e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—IL1B—multiple sclerosis	4.61e-06	3.65e-05	CbGpPWpGaD
Imatinib—LCK—Disease—CD4—multiple sclerosis	4.61e-06	3.64e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—POMC—multiple sclerosis	4.61e-06	3.64e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—IL2—multiple sclerosis	4.6e-06	3.63e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—BCHE—multiple sclerosis	4.59e-06	3.63e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—MYC—multiple sclerosis	4.59e-06	3.63e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—TGFB1—multiple sclerosis	4.58e-06	3.62e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—BCHE—multiple sclerosis	4.55e-06	3.6e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—MAPK1—multiple sclerosis	4.53e-06	3.58e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	4.51e-06	3.57e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—MAPK1—multiple sclerosis	4.49e-06	3.55e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—POMC—multiple sclerosis	4.47e-06	3.53e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TYK2—multiple sclerosis	4.45e-06	3.52e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—STAT3—multiple sclerosis	4.45e-06	3.52e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—MAPK1—multiple sclerosis	4.38e-06	3.46e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—IL2—multiple sclerosis	4.34e-06	3.43e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—POMC—multiple sclerosis	4.3e-06	3.39e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—MAPK1—multiple sclerosis	4.27e-06	3.37e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—ALB—multiple sclerosis	4.25e-06	3.35e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CD80—multiple sclerosis	4.23e-06	3.34e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—ALB—multiple sclerosis	4.21e-06	3.32e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—ALB—multiple sclerosis	4.2e-06	3.32e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—MYC—multiple sclerosis	4.13e-06	3.27e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—TGFB1—multiple sclerosis	4.12e-06	3.26e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	4.11e-06	3.25e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—IL2—multiple sclerosis	4.11e-06	3.25e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MMP9—multiple sclerosis	4.11e-06	3.25e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—TGFB1—multiple sclerosis	4.09e-06	3.23e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—ALB—multiple sclerosis	4.08e-06	3.22e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—MAPK1—multiple sclerosis	4.04e-06	3.2e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—POMC—multiple sclerosis	4.02e-06	3.18e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—MAPK1—multiple sclerosis	4.01e-06	3.17e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—IL6—multiple sclerosis	3.95e-06	3.12e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CCL2—multiple sclerosis	3.93e-06	3.11e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—ALB—multiple sclerosis	3.92e-06	3.09e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MMP9—multiple sclerosis	3.89e-06	3.07e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—BCHE—multiple sclerosis	3.89e-06	3.07e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—APOE—multiple sclerosis	3.88e-06	3.07e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—STAT3—multiple sclerosis	3.87e-06	3.06e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IL6—multiple sclerosis	3.74e-06	2.95e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IL2—multiple sclerosis	3.7e-06	2.93e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—STAT3—multiple sclerosis	3.65e-06	2.89e-05	CbGpPWpGaD
Imatinib—KIT—Disease—IL6—multiple sclerosis	3.64e-06	2.88e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TYK2—multiple sclerosis	3.57e-06	2.82e-05	CbGpPWpGaD
Imatinib—LCK—Disease—STAT3—multiple sclerosis	3.57e-06	2.82e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—MAPK1—multiple sclerosis	3.52e-06	2.78e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MMP9—multiple sclerosis	3.5e-06	2.77e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—IL6—multiple sclerosis	3.48e-06	2.75e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—STAT3—multiple sclerosis	3.46e-06	2.73e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—IL6—multiple sclerosis	3.45e-06	2.73e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MYC—multiple sclerosis	3.4e-06	2.68e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TGFB1—multiple sclerosis	3.39e-06	2.68e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IL6—multiple sclerosis	3.37e-06	2.66e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—APOE—multiple sclerosis	3.35e-06	2.64e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—POMC—multiple sclerosis	3.34e-06	2.64e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MAPK1—multiple sclerosis	3.32e-06	2.62e-05	CbGpPWpGaD
Imatinib—LCK—Disease—MYC—multiple sclerosis	3.32e-06	2.62e-05	CbGpPWpGaD
Imatinib—LCK—Disease—TGFB1—multiple sclerosis	3.31e-06	2.62e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—IL6—multiple sclerosis	3.28e-06	2.59e-05	CbGpPWpGaD
Imatinib—LCK—Disease—MAPK1—multiple sclerosis	3.25e-06	2.56e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MYC—multiple sclerosis	3.21e-06	2.54e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TGFB1—multiple sclerosis	3.21e-06	2.53e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MAPK1—multiple sclerosis	3.14e-06	2.48e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—STAT3—multiple sclerosis	3.12e-06	2.46e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—IL6—multiple sclerosis	3.11e-06	2.46e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—ALB—multiple sclerosis	3.04e-06	2.4e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—APOE—multiple sclerosis	3e-06	2.37e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—BCHE—multiple sclerosis	3e-06	2.37e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IL2—multiple sclerosis	2.97e-06	2.35e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—APOE—multiple sclerosis	2.93e-06	2.32e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MYC—multiple sclerosis	2.9e-06	2.29e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TGFB1—multiple sclerosis	2.89e-06	2.28e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—POMC—multiple sclerosis	2.87e-06	2.27e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MAPK1—multiple sclerosis	2.83e-06	2.24e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MMP9—multiple sclerosis	2.81e-06	2.22e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—APOE—multiple sclerosis	2.76e-06	2.18e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—APOE—multiple sclerosis	2.74e-06	2.16e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—IL6—multiple sclerosis	2.7e-06	2.13e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—POMC—multiple sclerosis	2.58e-06	2.04e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—IL6—multiple sclerosis	2.55e-06	2.02e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—POMC—multiple sclerosis	2.52e-06	1.99e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—STAT3—multiple sclerosis	2.5e-06	1.98e-05	CbGpPWpGaD
Imatinib—LCK—Disease—IL6—multiple sclerosis	2.49e-06	1.97e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—IL6—multiple sclerosis	2.42e-06	1.91e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—POMC—multiple sclerosis	2.37e-06	1.87e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—POMC—multiple sclerosis	2.35e-06	1.86e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—ALB—multiple sclerosis	2.35e-06	1.86e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—APOE—multiple sclerosis	2.34e-06	1.85e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MYC—multiple sclerosis	2.32e-06	1.84e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TGFB1—multiple sclerosis	2.32e-06	1.83e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—ALB—multiple sclerosis	2.3e-06	1.81e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MAPK1—multiple sclerosis	2.27e-06	1.8e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IL6—multiple sclerosis	2.18e-06	1.72e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—ALB—multiple sclerosis	2.16e-06	1.71e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—ALB—multiple sclerosis	2.14e-06	1.69e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—POMC—multiple sclerosis	2.01e-06	1.59e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ALB—multiple sclerosis	1.83e-06	1.45e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—APOE—multiple sclerosis	1.81e-06	1.43e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IL6—multiple sclerosis	1.75e-06	1.38e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—POMC—multiple sclerosis	1.55e-06	1.23e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ALB—multiple sclerosis	1.41e-06	1.12e-05	CbGpPWpGaD
